Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29719412 | 0.82 | CYP2C19 (0.54) | LMNACYP2C9CYP2C19NAMPTMAPT | |
| SCHEMBL4398673 | 0.82 | CYP2C19 (0.54) | LMNACYP2C9CYP2C19NAMPTMAPT | |
| SCHEMBL1810634 | 0.77 | NAMPT (0.45) | NAMPTMAPTKDM4ENPSR1CYP17A1 | |
| SCHEMBL4909589 | 0.77 | MAPT (0.44) | LMNAMAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL4908827 | 0.76 | CYP2C9 (0.52) | LMNACYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL9237307 | 0.76 | CYP17A1 (0.48) | NAMPTCYP17A1BCL2SREBF2 | |
| SCHEMBL12582106 | 0.76 | PTPN2 (0.48) | NAMPTCYP17A1BCL2 | |
| SCHEMBL273218 | 0.75 | PDK1 (0.60) | NAMPTMAPTKDM4ENPSR1SMN1; SMN2 | |
| SCHEMBL25260252 | 0.75 | MAOB (0.52) | LMNAMAPTKDM4ENPSR1SMN1; SMN2 | |
| SCHEMBL30529285 | 0.75 | MAOB (0.52) | LMNAMAPTKDM4ENPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | LMNA 1835/4885CYP2C9 215/4885CYP2C19 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.